- Wood Group Research Group
PhD, MSc, BSc
Postdoctoral Research Scientist/Laboratory Manager
Tom is the Wood group's lab manager and a postdoctoral researcher working on Duchenne muscular dystrophy and screening of FDA approved drugs to find synergistic benefits for our exon skipping regime. Tom’s background is in varied research including entomology, virology, and ribozyme therapy.
NOVEL CELL PENETRATING PEPTIDES FOR SKELETAL AND CARDIAC MUSCLE DELIVERY OF PMO ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
Hammond SM. et al, (2011), NUCLEIC ACID THERAPEUTICS, 21, A12 - A12
Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice
Yin H. et al, (2011), Molecular Therapy, 19, 1295 - 1303
Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice.
Yin H. et al, (2011), Mol Ther, 19, 1295 - 1303
Diaphragm rescue alone prevents heart dysfunction in dystrophic mice.
Crisp A. et al, (2011), Hum Mol Genet, 20, 413 - 421
Functional rescue of dystrophin-deficient mdx mice by a chimeric peptide-PMO.
Yin H. et al, (2010), Mol Ther, 18, 1822 - 1829